On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might ...

This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500 index climbed 25% ...

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

In a report released on November 7, Geoff Meacham from Citi maintained a Buy rating on Royalty Pharma (RPRX – Research Report). The company’s shares closed yesterday at $26.21. According to TipRanks, ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...